Skip to main content
. 2020 Dec 18;3(4):271–284. doi: 10.1093/abt/tbaa027

Figure 2.

Figure 2

(a) Site-specific conjugates (modified via β-Gal and EndoS2) showed higher tracer stability in plasma compared with non-specific (random) labeled conjugates in plasma. Mean tumor uptake is more elevated for site-specific conjugates (β-Gal and EndoS2) compared to non-specific (random) conjugates post-injection in mice (right) [6]. (b) Site-specific conjugation (mediated by transglutaminase) demonstrated a two-fold increase in binding efficiency compared with its non-specific counterpart (i.e., acylation of amines) [1]. (c) Site-specific conjugates (center and right panels) show less variability at a low concentrations between 10 nM and 10 pM compared with non-specific conjugates (left panel) [5]. (d) SPR analysis of trastuzumab conjugates formed by random conjugation (left panel) and site-specific conjugation to introduce DFO (Deferoxamine) and Biotin (center and right panels) [26]. The randomly labeled conjugate showed impaired binding compared with the site-specifically conjugated antibody. Modified and adapted with permission from Kristensen et al. [6], Sadiki et al. [1], Pellegrino et al. [5], and Genovis. Copyright © 2020, John Wiley and Sons; Copyright © 2014, American Chemical Society.